Vyne Therapeutics Inc.   Report issue

For profit Phase 2 Phase 3 Phase 4
Founded: Menlo Park CA United States (2011)
Status: Acquired by Foamix Ltd. (2019)

Organization Overview

First Clinical Trial
2013
NCT01951274
First Marketed Drug
2019
minocycline (minocin)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Acting Chief Medical Officer, Tigercat Pharma, Inc. | Menlo Therapeutics | Menlo Therapeutics Inc. | Tigercat Pharma, Inc. | VYNE | Vyne Therapeutics Inc.

Active Ingredients

Marketed Drugs (1)

minocycline (minocin) (2019)

Drugs in Phase 4 Trials (2)

isotretinoin (Accutane) (1 trial)

minocycline (minocin) (1 trial)

Drugs in Phase 3 Trials (1)

serlopitant (12 trials)

Drugs in Phase 2 Trials (2)

fingolimod (gilenya) (1 trial)

tofacitinib (xeljanz) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Burns (Phase 2)

Cough (Phase 2)

Dermatitis (Phase 3)

Dermatitis, Atopic (Phase 3)

Eczema (Phase 2)

Epidermolysis Bullosa (Phase 2)

Neurodermatitis (Phase 3)

Prurigo (Phase 3)

Pruritus (Phase 3)

Psoriasis (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 14
  • # of Trial APIs: 5